Industry bias.

This scientific expose reveals the breadth and depth of financial conflicts of interest among principal investigators (n=91) of currently occurring US Cooperative Group randomized oncology trials. Using the CMS Open Payments database, it was determined that median research funding was approximately $50K and median additional individual payments was approximately $1K. Higher payments, often much higher, were associated with the principal investigator having received previous payments from the manufacturer of the drug utilized in his/her trial, likely representing a longer physician-pharma relationship. | Metzger, Int J Cancer 2021

Comments

Popular Posts